John Parissis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9657563/publications.pdf

Version: 2024-02-01

250 papers 11,374 citations

51 h-index 95 g-index

254 all docs

254 docs citations

times ranked

254

13795 citing authors

#	Article	IF	CITATIONS
1	Left Atrial Deformation in Heart Failure: A Clinical Update. Current Problems in Cardiology, 2023, 48, 101183.	2.4	1
2	Assessment of acute heart failure prognosis: the promising role of prognostic models and biomarkers. Heart Failure Reviews, 2022, 27, 655-663.	3.9	7
3	Cognitive impairment in heart failure: clinical implications, tools of assessment, and therapeutic considerations. Heart Failure Reviews, 2022, 27, 993-999.	3.9	11
4	Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. Journal of Cardiovascular Translational Research, 2022, 15, 890-902.	2.4	13
5	Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease. Journal of Human Hypertension, 2022, 36, 1113-1120.	2.2	7
6	Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis. Pharmaceuticals, 2022, 15, 172.	3.8	5
7	The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature. European Heart Journal Supplements, 2022, 24, D22-D33.	0.1	6
8	Endothelial Dysfunction Is Associated with Decreased Nitric Oxide Bioavailability in Dysglycaemic Subjects and First-Degree Relatives of Type 2 Diabetic Patients. Journal of Clinical Medicine, 2022, 11, 3299.	2.4	3
9	Cardiac imaging in cardiotoxicity: a focus on clinical practice. Heart Failure Reviews, 2021, 26, 1175-1187.	3.9	13
10	Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock – Insights from the CardShock study. International Journal of Cardiology, 2021, 322, 191-196.	1.7	13
11	Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study. ESC Heart Failure, 2021, 8, 1398-1407.	3.1	13
12	Extracorporeal life support at the emergency department: new insights into the management of acute cardiac care patients. Hellenic Journal of Cardiology, 2021, 62, 46-47.	1.0	0
13	It's Not All about Echocardiography. Open the Lung Window for the Cardiac Emergencies. Medicina (Lithuania), 2021, 57, 69.	2.0	2
14	Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study. Basic Research in Cardiology, 2021, 116, 9.	5.9	24
15	The <scp>Heart Failure Association Atlas</scp> : <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	7.1	130
16	Association of ventricular–arterial interaction with the response to cardiac resynchronization therapy. European Journal of Heart Failure, 2021, 23, 1238-1240.	7.1	2
17	Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function. Scientific Reports, 2021, 11, 11808.	3.3	9
18	Association between upâ€titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	7.1	11

#	Article	IF	CITATIONS
19	Î#e association of heart failure across left ventricular ejection fraction with mortality in atrial fibrillation. ESC Heart Failure, 2021, 8, 3189-3197.	3.1	3
20	Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes. Antioxidants, 2021, 10, 1379.	5.1	15
21	Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a nonâ€randomized, openâ€label, proofâ€ofâ€concept study. European Journal of Heart Failure, 2021, 23, 593-597.	7.1	21
22	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews, 2021, 26, 861-879.	3.9	16
23	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. ESC Heart Failure, 2021, 8, 4717-4736.	3.1	9
24	Anticoagulation for atrial fibrillation in heart failure patients: balancing between Scylla and Charybdis. Journal of Geriatric Cardiology, 2021, 18, 352-361.	0.2	1
25	Current Use and Impact on 30-Day Mortality of Pulmonary Artery Catheter in Cardiogenic Shock Patients: Results From the CardShock Study. Journal of Intensive Care Medicine, 2020, 35, 1426-1433.	2.8	39
26	Heart failure and sepsis: practical recommendations for the optimal management. Heart Failure Reviews, 2020, 25, 183-194.	3.9	42
27	Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis. Canadian Journal of Cardiology, 2020, 36, 100-111.	1.7	46
28	Optimal Blood Pressure Control Improves Left Ventricular Torsional Deformation and Vascular Function in Newly Diagnosed Hypertensives: a 3-Year Follow-up Study. Journal of Cardiovascular Translational Research, 2020, 13, 814-825.	2.4	15
29	Acutely decompensated versus acute heart failure: two different entities. Heart Failure Reviews, 2020, 25, 907-916.	3.9	13
30	Safety and efficacy of salt substitution with a low sodium-potassium enriched dietary salt in patients with heart failure with reduced ejection fraction: A pilot study. Clinical Nutrition ESPEN, 2020, 35, 90-94.	1.2	14
31	Serum Lactate and A Relative Change in Lactate as Predictors of Mortality in Patients With Cardiogenic Shock – Results from the Cardshock Study. Shock, 2020, 53, 43-49.	2.1	15
32	Distribution, infrastructure, and expertise of heart failure and cardioâ€oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413.	3.1	6
33	Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. Food and Chemical Toxicology, 2020, 145, 111694.	3.6	45
34	UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure. Diagnostic and Prognostic Research, 2020, 4, 13.	1.8	4
35	The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19). Frontiers in Cardiovascular Medicine, 2020, 7, 129.	2.4	14
36	Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke. Annals of Neurology, 2020, 88, 946-955.	5. 3	24

#	Article	IF	CITATIONS
37	MitraClip and left ventricular reverse remodelling: a strain imaging study. ESC Heart Failure, 2020, 7, 1409-1418.	3.1	33
38	Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group. Infectious Diseases and Therapy, 2020, 9, 407-416.	4.0	17
39	A novel strategy for the management of lung congestion: targeting <scp>TRPV4</scp> channel, the †gate keeper†of pulmonary capillary permeability. European Journal of Heart Failure, 2020, 22, 1646-1648.	7.1	0
40	Epidemiology, pathophysiology and contemporary management of cardiogenic shock–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
41	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	3.9	15
42	<scp>¹⁸Fâ€FDG PET</scp> / <scp>CT</scp> brain glucose metabolism as a marker of different types of depression comorbidity in chronic heart failure patients with impaired systolic function. European Journal of Heart Failure, 2020, 22, 2138-2146.	7.1	8
43	Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease. Medicina (Lithuania), 2020, 56, 305.	2.0	6
44	Heart failure in the course of a pandemic. European Journal of Heart Failure, 2020, 22, 1755-1758.	7.1	5
45	Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. ESC Heart Failure, 2020, 7, 768-773.	3.1	4
46	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
47	Inotropic agents in cardiogenic shock. Current Opinion in Critical Care, 2020, Publish Ahead of Print, 403-410.	3.2	3
48	How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Failure, 2020, 7, 15-25.	3.1	10
49	l^2-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis, 2020, 49, 365-376.	2.1	11
50	Association of impaired arterial wall properties with the presence of coronary artery disease in patients with abdominal aortic aneurysms. Journal of Clinical Hypertension, 2020, 22, 187-193.	2.0	3
51	Pregnancy in a Patient With Tetralogy of Fallot and Borderline Pulmonary Arterial Hypertension. JACC: Case Reports, 2020, 2, 91-95.	0.6	0
52	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
53	Effects of Glucagonâ€Like Peptideâ€1 Receptor Agonists, Sodiumâ€Glucose Cotransporterâ€2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12â€Month Treatment. Journal of the American Heart Association. 2020. 9. e015716.	3.7	106
54	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37

#	Article	IF	Citations
55	Telephone based survey in adults with congenital heart disease during COVID-19 pandemic. Cardiology Journal, 2020, 27, 636-638.	1.2	8
56	Impaired Arterial Elastic Properties and Endothelial Glycocalyx in Patients with Embolic Stroke of Undetermined Source. Thrombosis and Haemostasis, 2019, 119, 1860-1868.	3.4	22
57	Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow–Up Study. Journal of Clinical Medicine, 2019, 8, 983.	2.4	25
58	Short-Term Therapies for Treatment of Acute and Advanced Heart Failureâ€"Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	2.4	14
59	Measurement of central augmentation index by three different methods and techniques: Agreement among Arteriograph, Complior, and Mobilâ€Oâ€Graph devices. Journal of Clinical Hypertension, 2019, 21, 1386-1392.	2.0	15
60	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
61	Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?. European Journal of Heart Failure, 2019, 21, 767-769.	7.1	10
62	Pulse wave analysis using the Mobil-O-Graph, Arteriograph and Complior device: a comparative study. Blood Pressure, 2019, 28, 107-113.	1.5	31
63	Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. European Journal of Heart Failure, 2019, 21, 1353-1365.	7.1	56
64	Oral anticoagulation in patients with chronic kidney disease. Neurology, 2019, 92, e2421-e2431.	1.1	36
65	Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions. European Journal of Internal Medicine, 2019, 65, 17-25.	2.2	8
66	Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. PLoS ONE, 2019, 14, e0217006.	2.5	31
67	Imaging Risk in Multisystem Inflammatory Diseases. JACC: Cardiovascular Imaging, 2019, 12, 2517-2537.	5.3	11
68	Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clinical Research in Cardiology, 2019, 108, 1093-1101.	3.3	41
69	The role of ventriculara arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Seripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. European Journal of Heart Failure, 2019, 21,	7.1	202
70	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
71	Vaccination in Patients With Heart Disease. How Long Should We Wait? Response. Revista Espanola De Cardiologia (English Ed), 2019, 72, 516.	0.6	0
72	Risk in atrial fibrillation: left atrial function matters. European Journal of Heart Failure, 2019, 21, 1584-1585.	7.1	1

#	Article	IF	Citations
73	Potential Utility of Neurosonology in Paroxysmal Atrial Fibrillation Detection in Patients with Cryptogenic Stroke. Journal of Clinical Medicine, 2019, 8, 2002.	2.4	8
74	Practical Recommendations for the Diagnosis and Medical Management of Stable Angina. Journal of Cardiovascular Pharmacology, 2019, 74, 308-314.	1.9	4
75	Pulse wave velocity to global longitudinal strain ratio in hypertension. European Journal of Clinical Investigation, 2019, 49, e13049.	3.4	37
76	Comparative Analysis of Short-Term Outcomes of Patients With Heart Failure With a Mid-Range Ejection Fraction After Acute Decompensation. American Journal of Cardiology, 2019, 123, 84-92.	1.6	12
77	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. Cardiac Failure Review, 2019, 5, 155-161.	3.0	13
78	Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice. Cardiac Failure Review, 2019, 5, 133-139.	3.0	34
79	Association of impaired endothelial glycocalyx with arterial stiffness, coronary microcirculatory dysfunction, and abnormal myocardial deformation in untreated hypertensives. Journal of Clinical Hypertension, 2018, 20, 672-679.	2.0	55
80	Vaccination in Heart Failure: An Approach to Improve Outcomes. Revista Espanola De Cardiologia (English Ed), 2018, 71, 697-699.	0.6	2
81	The association of adult vaccination with the risk of cerebrovascular ischemia: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2018, 386, 12-18.	0.6	31
82	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews, 2018, 23, 377-388.	3.9	16
83	Electronic Cigarette Smoking Increases Arterial Stiffness and Oxidative Stress to a Lesser Extent Than a Single Conventional Cigarette. Circulation, 2018, 137, 303-306.	1.6	81
84	Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure. European Journal of Heart Failure, 2018, 20, 614-616.	7.1	11
85	Mortalidad tras un episodio de insuficiencia cardiaca aguda en una cohorte de pacientes con funci $ ilde{A}^3$ n ventricular intermedia: an $ ilde{A}_i$ lisis global y en relaci $ ilde{A}^3$ n con el lugar de ingreso. Medicina Cl $ ilde{A}^3$ nica, 2018, 151, 223-230.	0.6	3
86	Prognostic significance of global longitudinal strain in chronic kidney disease: the evidence is building. European Journal of Heart Failure, 2018, 20, 569-571.	7.1	6
87	Congestion in acute heart failure with reduced vs. preserved left ventricular ejection fraction: differences, similarities and remaining gaps. European Journal of Heart Failure, 2018, 20, 748-750.	7.1	5
88	Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 897-913.	3.3	77
89	Natriuretic peptides in acute coronary syndromes: A new role to predict recurrent ischemic event-related mortality?. Hellenic Journal of Cardiology, 2018, 59, 119-121.	1.0	2
90	Comprehensive inâ€hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	7.1	57

#	Article	IF	CITATIONS
91	Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factorâ€A in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2018, 20, 1162-1163.	7.1	2
92	Altered mental status predicts mortality in cardiogenic shock – results from the CardShock study. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 38-44.	1.0	26
93	Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications. Heart Failure Reviews, 2018, 23, 55-61.	3.9	11
94	Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure, 2018, 20, 572-581.	7.1	68
95	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of Cardiovascular Pharmacology, 2018, 71, 129-136.	1.9	33
96	Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 76-86.	3.3	15
97	Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications. European Journal of Heart Failure, 2018, 20, 436-444.	7.1	31
98	Ups and downs in heart failure: the case of proteomics. European Journal of Heart Failure, 2018, 20, 63-66.	7.1	6
99	Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure. Cardiology, 2018, 141, 98-106.	1.4	35
100	Implantable devices to monitor patients with heart failure. Heart Failure Reviews, 2018, 23, 849-857.	3.9	4
101	Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. Cardiology, 2018, 140, 126-132.	1.4	19
102	Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovascular Diabetology, 2018, 17, 8.	6.8	102
103	Mortality after an episode of acute heart failure in a cohort of patients with intermediate ventricular function: Global analysis and relationship with admission department. Medicina ClÃnica (English) Tj ETQq1 1 0.78-	4 ∂. 24 rgBT	Dverlock
104	Percutaneous patent foramen ovale closure for secondary stroke prevention. Neurology, 2018, 91, e8-e18.	1.1	30
105	Early detection of left ventricular dysfunction in first-degree relatives of diabetic patients by myocardial deformation imaging: The role of endothelial glycocalyx damage. International Journal of Cardiology, 2017, 233, 105-112.	1.7	30
106	Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4â€year followâ€up study. European Journal of Heart Failure, 2017, 19, 846-861.	7.1	23
107	Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy, 2017, 121, 363-377.	3.0	43
108	Effect of functional electrical stimulation on cardiovascular outcomes in patients with chronic heart failure. European Journal of Preventive Cardiology, 2017, 24, 833-839.	1.8	11

#	Article	IF	Citations
109	Duration of paroxysmal atrial fibrillation in cryptogenic stroke is not associated with stroke severity and early outcomes. Journal of the Neurological Sciences, 2017, 376, 191-195.	0.6	9
110	Influenza infection and heart failureâ€"vaccination may change heart failure prognosis?. Heart Failure Reviews, 2017, 22, 329-336.	3.9	36
111	Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. Atherosclerosis, 2017, 262, 123-130.	0.8	45
112	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	7.1	252
113	Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Critical Care Medicine, 2017, 45, e666-e673.	0.9	25
114	Phenotyping heart failure with preserved ejection fraction by echocardiography: a light in the tunnel?. European Heart Journal Cardiovascular Imaging, 2017, 18, 636-638.	1.2	0
115	Epidemiology and oneâ€year outcomes in patients with chronic heart failure and preserved, midâ€range and reduced ejection fraction: an analysis of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	7.1	568
116	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368.	3.3	57
117	Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. International Journal of Cardiology, 2017, 230, 191-197.	1.7	33
118	The Cardio-Renal Interrelationship. Progress in Cardiovascular Diseases, 2017, 59, 636-648.	3.1	39
119	Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, andÂmanagement. European Journal of Heart Failure, 2017, 19, 479-489.	7.1	31
120	Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process. Journal of the American Society of Echocardiography, 2017, 30, 1091-1102.	2.8	21
121	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. American Journal of Cardiology, 2017, 120, 1090-1097.	1.6	17
122	Plasma Glial Fibrillary Acidic Protein in the Differential Diagnosis of Intracerebral Hemorrhage. Stroke, 2017, 48, 2586-2588.	2.0	58
123	Nitroxyl donors for acute heart failure: promising newcomers. European Journal of Heart Failure, 2017, 19, 1333-1334.	7.1	8
124	Blood Pressure Reduction and Secondary Stroke Prevention. Hypertension, 2017, 69, 171-179.	2.7	140
125	The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock $\hat{a} \in \mathbb{C}$ Results from the CardShock Study. International Journal of Cardiology, 2017, 226, 48-52.	1.7	38
126	The interplay between renin-angiotensin system activation, abnormal myocardial deformation and neurohumoral activation in hypertensive heart disease: a speckle tracking echocardiography study. International Journal of Cardiovascular Imaging, 2017, 33, 323-329.	1.5	8

#	Article	IF	Citations
127	Chitinase-3-like protein-1 (YKL-40) before and after therapy in supraventricular arrhythmias. Journal of Cardiovascular Medicine, 2017, 18, 650-654.	1.5	1
128	Cardiac Biomarkers Predict 1-Year Mortality in Elderly Patients Undergoing Hip Fracture Surgery. Orthopedics, 2017, 40, e417-e424.	1.1	25
129	Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 583-590.	1.9	3
130	Immunosenescence in patients with chronic systolic heart failure. Journal of Cardiovascular Medicine, 2016, 17, 624-630.	1.5	12
131	Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy metaâ€analysis. Annals of Neurology, 2016, 79, 625-635.	5.3	96
132	Heart failure registries: how far can we go?. European Journal of Heart Failure, 2016, 18, 626-628.	7.1	8
133	Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Therapeutic Advances in Neurological Disorders, 2016, 9, 359-368.	3.5	25
134	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	7.1	169
135	The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology, 2016, 87, 988-995.	1.1	71
136	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312.	1.7	103
137	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	7.1	455
138	Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. International Journal of Cardiology, 2016, 223, 781-784.	1.7	9
139	Structured discharge instructions for hospitalized heart failure patients to improve guideline implementation and patient outcomes. International Journal of Cardiology, 2016, 220, 143-145.	1.7	3
140	The Model for Endâ€stage Liver Disease score inÂacute heart failure: hepatorenal dysfunction hides behind. European Journal of Heart Failure, 2016, 18, 1522-1523.	7.1	4
141	Global left atrial failure in heart failure. European Journal of Heart Failure, 2016, 18, 1307-1320.	7.1	104
142	Natriuretic peptides revisited. Journal of Cardiovascular Medicine, 2016, 17, 840-842.	1.5	2
143	Body mass index in acute heart failure: association with clinical profile, therapeutic management and inâ€hospital outcome. European Journal of Heart Failure, 2016, 18, 298-305.	7.1	25
144	Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. European Journal of Heart Failure, 2016, 18, 822-829.	7.1	28

#	Article	IF	Citations
145	Diet and Exercise for Obese Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 2618.	7.4	0
146	Heart failure and the risk of ischemic stroke recurrence: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2016, 362, 182-187.	0.6	32
147	Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Review of Clinical Pharmacology, 2016, 9, 513-523.	3.1	7
148	The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. International Journal of Cardiology, 2016, 203, 279-281.	1.7	64
149	Association of arterial stiffness with coronary flow reserve in revascularized coronary artery disease patients. World Journal of Cardiology, 2016, 8, 231.	1.5	17
150	Functional electrical stimulation of lower limb muscles as an alternative mode of exercise training in chronic heart failure: practical considerations and proposed algorithm. European Journal of Heart Failure, 2015, 17, 1228-1230.	7.1	19
151	Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study. BMC Health Services Research, 2015, 15, 566.	2.2	6
152	Depressive Symptoms in Patients with Congenital Heart Disease: Incidence and Prognostic Value of Self-Rating Depression Scales. Congenital Heart Disease, 2015, 10, 240-247.	0.2	29
153	Overcoming the ethnic differences in patients hospitalized for heart failure: is there a need for international harmonization of clinical practice guidelines?. European Journal of Heart Failure, 2015, 17, 755-757.	7.1	5
154	Association of impaired left ventricular twistingâ€untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. European Journal of Heart Failure, 2015, 17, 1240-1251.	7.1	63
155	B-type natriuretic peptide vs. cardiac risk scores for prediction of outcome following major orthopedic surgery. Journal of Cardiovascular Medicine, 2015, 16, 465-471.	1.5	11
156	Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction. Journal of Cardiovascular Medicine, 2015, 16, 341-346.	1.5	37
157	Similarities in Coronary Function and Myocardial Deformation Between Psoriasis and Coronary Artery Disease: The Role of Oxidative Stress and Inflammation. Canadian Journal of Cardiology, 2015, 31, 287-295.	1.7	59
158	Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. International Journal of Cardiology, 2015, 182, 74-76.	1.7	15
159	Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Revista Espanola De Cardiologia (English Ed), 2015, 68, 245-248.	0.6	64
160	Acute Heart Failure Syndromes in the Elderly. Heart Failure Clinics, 2015, 11, 637-645.	2.1	18
161	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology, 2015, 191, 256-264.	1.7	125
162	Clinical picture and risk prediction of shortâ€term mortality in cardiogenic shock. European Journal of Heart Failure, 2015, 17, 501-509.	7.1	520

#	Article	IF	CITATIONS
163	Rapid normalization of vasculitis-induced left ventricular dysfunction related with multiple cardiac thrombi. Journal of Thrombosis and Thrombolysis, 2015, 40, 395-399.	2.1	2
164	Myocardial deformation imaging unmasks subtle left ventricular systolic dysfunction in asymptomatic and treatment-naà ve HIV patients. Clinical Research in Cardiology, 2015, 104, 975-981.	3.3	14
165	Efficacy and safety of functional electrical stimulation of lower limb muscles in elderly patients with chronic heart failure: A pilot study. European Journal of Preventive Cardiology, 2015, 22, 831-836.	1.8	19
166	Insulin resistance and acute glucose changes determine arterial elastic properties and coronary flow reserve in dysglycaemic and first-degree relatives of diabetic patients. Atherosclerosis, 2015, 241, 455-462.	0.8	25
167	The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio. Therapeutic Advances in Neurological Disorders, 2015, 8, 245-254.	3.5	9
168	In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236.	1.7	31
169	Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology, 2015, 180, 46-49.	1.7	35
170	Recurrent Stroke and Patent Foramen Ovale. Stroke, 2014, 45, 3352-3359.	2.0	67
171	Heart Failure Association of the <scp>European Society of Cardiology</scp> Specialist Heart Failure Curriculum. European Journal of Heart Failure, 2014, 16, 151-162.	7.1	52
172	Increased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients With Coronary Artery Disease and Coexisting Rheumatoid Arthritis. Circulation: Cardiovascular Imaging, 2014, 7, 619-628.	2.6	132
173	Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2014, 15, 476-480.	1.5	3
174	Insights Into Onco-Cardiology. Journal of the American College of Cardiology, 2014, 63, 945-953.	2.8	295
175	Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: A systematic review and meta-analysis. International Journal of Cardiology, 2014, 175, 195-198.	1.7	44
176	Coronary flow reserve is associated with tissue ischemia and is an additive predictor of intensive care unit mortality to traditional risk scores in septic shock. International Journal of Cardiology, 2014, 172, 103-108.	1.7	22
177	Renal dysfunction and heart failure: things are seldom what they seem. European Heart Journal, 2014, 35, 416-418.	2.2	58
178	Clinical and prognostic implications of plasma NGAL and NT-proBNP in adult patients with congenital heart disease. International Journal of Cardiology, 2014, 177, 1026-1030.	1.7	7
179	Dobutamine-induced changes of multidimensional cardiac deformation predict functional capacity in patients with advanced systolic heart failure. International Journal of Cardiology, 2014, 176, 1438-1440.	1.7	5
180	Clinical and echocardiographic correlates of serum copper and zinc in acute and chronic heart failure. Clinical Research in Cardiology, 2014, 103, 938-949.	3.3	43

#	Article	IF	CITATIONS
181	Selenium contributes to myocardial injury and cardiac remodeling in heart failure. International Journal of Cardiology, 2014, 176, 272-273.	1.7	18
182	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology, 2014, 172, 115-121.	1.7	96
183	Novel Biomarkers in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1654-1656.	2.8	7
184	Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis, 2014, 234, 34-41.	0.8	34
185	Cardiovascular Prevention in Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2053-2054.	2.8	0
186	Medical management of stable angina. Hellenic Journal of Cardiology, 2014, 55, 272-80.	1.0	4
187	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction. American Heart Journal, 2013, 166, 760-767.	2.7	45
188	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	7.1	75
189	Gender-related differences in patients with acute heart failure: Management and predictors of in-hospital mortality. International Journal of Cardiology, 2013, 168, 185-189.	1.7	36
190	Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 1122-1130.	7.1	23
191	The evaluation of pulse wave velocity using Arteriograph and Complior apparatus across multiple cohorts of cardiovascular-related diseases. International Journal of Cardiology, 2013, 168, 4890-4892.	1.7	21
192	Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels. International Journal of Cardiology, 2013, 168, 3609-3612.	1.7	34
193	Renal Effects of Levosimendan: A Consensus Report. Cardiovascular Drugs and Therapy, 2013, 27, 581-590.	2.6	65
194	Intravenous ferric carboxymaltose in ironâ€deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIRâ€HF trial. European Journal of Heart Failure, 2013, 15, 1267-1276.	7.1	130
195	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	7.1	645
196	Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. European Heart Journal, 2013, 34, 742-749.	2.2	234
197	Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 256-268.	1.0	19
198	The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infraction. Atherosclerosis, 2012, 223, 184-189.	0.8	15

#	Article	IF	Citations
199	Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure. International Journal of Cardiology, 2012, 157, 31-37.	1.7	5
200	Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality. International Journal of Cardiology, 2012, 157, 108-113.	1.7	51
201	Inflammatory markers in coronary artery disease. BioFactors, 2012, 38, 320-328.	5.4	46
202	Impact of diuretic dosing on mortality in acute heart failure using a propensityâ€matched analysis. European Journal of Heart Failure, 2011, 13, 1244-1252.	7.1	52
203	Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. Thrombosis and Haemostasis, 2011, 106, 959-967.	3.4	14
204	The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease. Reviews on Recent Clinical Trials, 2011, 6, 108-113.	0.8	20
205	Clinical Characteristics and Predictors of In-Hospital Mortality in Acute Heart Failure With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 79-84.	1.6	38
206	Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Medicine, 2011, 37, 290-301.	8.2	196
207	Congenital left ventricular aneurysm: a cause of impaired myocardial torsion and peripheral thrombo-embolic events. European Journal of Echocardiography, 2011, 12, E7-E7.	2.3	11
208	Inotropes in cardiac patients: update 2011. Current Opinion in Critical Care, 2010, 16, 432-441.	3.2	43
209	Acute pulmonary oedema: clinical characteristics, prognostic factors, and inâ€hospital management. European Journal of Heart Failure, 2010, 12, 1193-1202.	7.1	45
210	EUR <i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	7.1	340
211	Incremental predictive value of carotid intima–media thickness to arterial stiffness for impaired coronary flow reserve in untreated hypertensives. Hypertension Research, 2010, 33, 367-373.	2.7	20
212	Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. International Journal of Cardiology, 2010, 139, 150-158.	1.7	43
213	Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in \hat{l}^2 -thalassemia major. American Heart Journal, 2010, 159, 68-74.	2.7	44
214	Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opinion on Investigational Drugs, 2009, 18, 695-707.	4.1	18
215	Selfâ€assessment of health status is associated with inflammatory activation and predicts longâ€term outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 163-169.	7.1	51
216	The prognostic role of echocardiographic indices in chronic heart failure: right ventricle revisited. European Journal of Heart Failure, 2009, 11, 1220-1220.	7.1	2

#	Article	IF	Citations
217	Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. European Journal of Heart Failure, 2009, 11, 967-972.	7.1	33
218	Clinical and Prognostic Value of Duke's Activity Status Index Along With Plasma B-Type Natriuretic Peptide Levels in Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2009, 103, 73-75.	1.6	41
219	Hyponatremia in heart failure. Heart Failure Reviews, 2009, 14, 59-63.	3.9	54
220	Levosimendan: from basic science to clinical practice. Heart Failure Reviews, 2009, 14, 265-275.	3.9	48
221	Two-dimensional strain analysis in patients with hypertrophic cardiomyopathy and normal systolic function: A 12-month follow-up study. American Heart Journal, 2009, 158, 444-450.	2.7	41
222	Clinical value of B-type natriuretic peptide for the assessment of left ventricular filling pressures in patients with systolic heart failure and inconclusive tissue Doppler indexes. Heart and Vessels, 2008, 23, 181-186.	1.2	14
223	The role of left ventricular long axis contraction in patients with asymptomatic non-ischemic mitral valve regurgitation and normal systolic function. International Journal of Cardiology, 2008, 124, 64-71.	1.7	16
224	Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opinion on Investigational Drugs, 2008, 17, 1143-1150.	4.1	38
225	Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: A randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2008, 10, 709-713.	7.1	38
226	Depression in coronary artery disease: Novel pathophysiologic mechanisms and therapeutic implications. International Journal of Cardiology, 2007, 116, 153-160.	1.7	58
227	Sertraline for the treatment of depression in coronary artery disease and heart failure. Expert Opinion on Pharmacotherapy, 2007, 8, 1529-1537.	1.8	14
228	Levosimendan, Compared to Dobutamine, Reduces Enzymatic Markers Associated with Liver Congestion and Right Heart Failure: A SURVIVE Subanalysis. Journal of Cardiac Failure, 2007, 13, S142.	1.7	0
229	Response to Editor:. Journal of Cardiovascular Electrophysiology, 2007, 18, E16-E16.	1.7	0
230	Ventricular Long-Axis Contraction as an Earlier Predictor of Outcome in Asymptomatic Aortic Regurgitation. American Journal of Cardiology, 2007, 100, 1677-1682.	1.6	21
231	Classical inotropes and new cardiac enhancers. Heart Failure Reviews, 2007, 12, 149-156.	3.9	79
232	Effects of Levosimendan on Quality of Life and Emotional Stress in Advanced Heart Failure Patients. Cardiovascular Drugs and Therapy, 2007, 21, 263-268.	2.6	20
233	The Role of Left Ventricular Long-axis Contraction in Patients with Asymptomatic Aortic Regurgitation. Journal of the American Society of Echocardiography, 2006, 19, 249-254.	2.8	32
234	Tissue Doppler Imaging Analysis at Pre-Cardioversion Time Predicts Recurrent Atrial Fibrillation: A 12-Month Follow-Up Study. Journal of Cardiovascular Electrophysiology, 2006, 17, 1005-1010.	1.7	6

#	Article	IF	CITATIONS
235	Effects of Levosimendan on Right Ventricular Function in Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 98, 1489-1492.	1.6	103
236	Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?. Current Pharmaceutical Design, 2006, 12, 2689-2699.	1.9	15
237	Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. American Journal of Cardiology, 2005, 96, 423-426.	1.6	94
238	Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches. Expert Opinion on Investigational Drugs, 2005, 14, 567-577.	4.1	44
239	Levosimendan for the treatment of acute heart failure syndromes. Expert Opinion on Pharmacotherapy, 2005, 6, 2741-2751.	1.8	36
240	A Case of Drug-Induced Pneumonitis Caused by Carvedilol. Respiration, 2004, 71, 650-652.	2.6	7
241	Plasma profiles of circulating granulocyte-macrophage colony-stimulating factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to post-infarction left ventricular dysfunction. European Cytokine Network, 2004, 15, 139-44.	2.0	16
242	Well-functioning double-orifice mitral valve in a young adult. Journal of Clinical Ultrasound, 2003, 31, 170-173.	0.8	11
243	Elevated Plasma Amylase Levels in Advanced Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy: Correlation with Circulating Interleukin-6 Activity. Journal of Interferon and Cytokine Research, 2003, 23, 329-333.	1.2	12
244	Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications. Current Molecular Medicine, 2003, 3, 139-147.	1.3	16
245	Serum Profiles of C-C Chemokines in Acute Myocardial Infarction: Possible Implication in Postinfarction Left Ventricular Remodeling. Journal of Interferon and Cytokine Research, 2002, 22, 223-229.	1.2	83
246	Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fasligand system in patients with chronic heart failure. Journal of the American College of Cardiology, 2002, 39, 653-663.	2.8	228
247	Cytokines and anti-cytokine therapeutic approaches to chronic heart failure. European Journal of Internal Medicine, 2002, 13, 356-364.	2.2	5
248	Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. International Journal of Cardiology, 2002, 83, 13-21.	1.7	93
249	Comparison of myocardial fractional flow reserve and intravascular ultrasound for the assessment of slotted-tube stents. Catheterization and Cardiovascular Interventions, 2001, 52, 322-326.	1.7	8
250	Detection of microsatellite instability in sporadic cardiac myxomas. Cardiovascular Research, 1999, 42, 728-732.	3.8	7